當前位置:BPS Bioscience Inc.>>CAR T-Cell Therapy Cell Lines>> 79755BCMA / NF-κB – Reporter HEK293 Recombinant Cell Line
Anti-BCMA CAR /NFAT (Luciferase) Re
Anti-CD19 CAR / NFAT (Luciferase) R
The BCMA / NF-κB - HEK293 recombinant cell line has been transfected with full-length human BCMA cDNA (Genbank #NM_001192) under control of a CMV promoter for high constitutive expression. The NF-κB–luciferase reporter is also stably integrated into the genome. The firefly luciferase gene is controlled by four copies of the NF-κB Response Element upstream of a minimal promoter. Upon ligand binding, active BCMA will initiate the NF-κB signaling pathway, leading to expression of the NF-κB-controlled luciferase reporter.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
請輸入賬號
請輸入密碼
請輸驗證碼
以上信息由企業自行提供,信息內容的真實性、準確性和合法性由相關企業負責,化工儀器網對此不承擔任何保證責任。
溫馨提示:為規避購買風險,建議您在購買產品前務必確認供應商資質及產品質量。